5 pending office actions • 3 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Akebia Therapeutics, Inc. | 2 |
| Mitsubishi Tanabe Pharma Corporation | 2 |
| Keryx Biopharmaceuticals, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18743646 | FERRIC CITRATE DOSAGE FORMS | Keryx Biopharmaceuticals, Inc. | PROSSER, ALISSA J | 1619 | Non-Final OA | Jun 14, 2024 |
| 18500471 | Compositions and Methods for Treating Anemia | Akebia Therapeutics, Inc. | YOO, SUN JAE | 1621 | Non-Final OA | Nov 02, 2023 |
| 18001917 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | Mitsubishi Tanabe Pharma Corporation | ANDERSON, JAMES D | 1629 | Non-Final OA | Dec 15, 2022 |
| 17906650 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics, Inc. | SAMSELL, RILLA MARIE | 1624 | Final Rejection | Sep 19, 2022 |
| 17772856 | THERAPEUTIC METHODS USING VADADUSTAT | Mitsubishi Tanabe Pharma Corporation | SZNAIDMAN, MARCOS L | 1628 | Final Rejection | Apr 28, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial